These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 31632814)

  • 21. Association of serum proprotein convertase subtilisin/kexin type 9 with early atherosclerosis in newly diagnosed type 2 diabetes mellitus.
    Guo W; Gong Y; Li J; Qin P; Lu J; Li X; Zhu W; Xu N; Zhou H; Zhang Q
    Nutr Metab Cardiovasc Dis; 2019 Aug; 29(8):815-821. PubMed ID: 31133497
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PCSK9 and diabetes: is there a link?
    Momtazi AA; Banach M; Pirro M; Stein EA; Sahebkar A
    Drug Discov Today; 2017 Jun; 22(6):883-895. PubMed ID: 28111330
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Inhibition: A Lipocrinologic Review.
    Kalra S
    J Assoc Physicians India; 2018 Oct; 66(10):70-72. PubMed ID: 31317713
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of the association between plasma PCSK9 and Lp(a) in Han Chinese.
    Yang SH; Li S; Zhang Y; Xu RX; Zhu CG; Guo YL; Wu NQ; Qing P; Gao Y; Cui CJ; Dong Q; Sun J; Li JJ
    J Endocrinol Invest; 2016 Aug; 39(8):875-83. PubMed ID: 26894681
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasma proprotein convertase subtilisin kexin type 9 is not altered in subjects with impaired glucose metabolism and type 2 diabetes mellitus, but its relationship with non-HDL cholesterol and apolipoprotein B may be modified by type 2 diabetes mellitus: The CODAM study.
    Brouwers MC; Troutt JS; van Greevenbroek MM; Ferreira I; Feskens EJ; van der Kallen CJ; Schaper NC; Schalkwijk CG; Konrad RJ; Stehouwer CD
    Atherosclerosis; 2011 Jul; 217(1):263-7. PubMed ID: 21497351
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of PCSK9 beyond liver involvement.
    Cariou B; Si-Tayeb K; Le May C
    Curr Opin Lipidol; 2015 Jun; 26(3):155-61. PubMed ID: 25887680
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Key aspects of PCSK9 inhibition beyond LDL lowering.
    Ramin-Mangata S; Blanchard V; Lambert G
    Curr Opin Lipidol; 2018 Dec; 29(6):453-458. PubMed ID: 30199407
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting PCSK9 for therapeutic gains: Have we addressed all the concerns?
    Banerjee Y; Santos RD; Al-Rasadi K; Rizzo M
    Atherosclerosis; 2016 May; 248():62-75. PubMed ID: 26987067
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Research progress on alternative non-classical mechanisms of PCSK9 in atherosclerosis in patients with and without diabetes.
    Tang Y; Li SL; Hu JH; Sun KJ; Liu LL; Xu DY
    Cardiovasc Diabetol; 2020 Mar; 19(1):33. PubMed ID: 32169071
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [PCSK9 inhibitors in hypercholesterolemia. New hope for patients with diabetes mellitus?].
    Parhofer KG
    Herz; 2016 May; 41(3):217-23. PubMed ID: 26961236
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Circulating PCSK9 levels are not associated with the severity of hepatic steatosis and NASH in a high-risk population.
    Wargny M; Ducluzeau PH; Petit JM; Le May C; Smati S; Arnaud L; Pichelin M; Bouillet B; Lannes A; Blanchet O; Lefebvre P; Francque S; Van Gaal L; Staels B; Vergès B; Boursier J; Cariou B
    Atherosclerosis; 2018 Nov; 278():82-90. PubMed ID: 30261472
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PCSK9 inhibition: the dawn of a new age in cholesterol lowering?
    Preiss D; Mafham M
    Diabetologia; 2017 Mar; 60(3):381-389. PubMed ID: 28025677
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment.
    Lambert G; Ancellin N; Charlton F; Comas D; Pilot J; Keech A; Patel S; Sullivan DR; Cohn JS; Rye KA; Barter PJ
    Clin Chem; 2008 Jun; 54(6):1038-45. PubMed ID: 18436719
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of Insulin in the Regulation of Proprotein Convertase Subtilisin/Kexin Type 9.
    Miao J; Manthena PV; Haas ME; Ling AV; Shin DJ; Graham MJ; Crooke RM; Liu J; Biddinger SB
    Arterioscler Thromb Vasc Biol; 2015 Jul; 35(7):1589-96. PubMed ID: 26023080
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plasma PCSK9 is increased by fenofibrate and atorvastatin in a non-additive fashion in diabetic patients.
    Costet P; Hoffmann MM; Cariou B; Guyomarc'h Delasalle B; Konrad T; Winkler K
    Atherosclerosis; 2010 Sep; 212(1):246-51. PubMed ID: 20619837
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acute and Chronic Impact of Bariatric Surgery on Plasma LDL Cholesterol and PCSK9 Levels in Patients With Severe Obesity.
    Boyer M; Piché ME; Auclair A; Grenier-Larouche T; Biertho L; Marceau S; Hould FS; Biron S; Lebel S; Lescelleur O; Julien F; Martin J; Tchernof A; Carpentier AC; Poirier P; Arsenault BJ
    J Clin Endocrinol Metab; 2017 Nov; 102(11):4023-4030. PubMed ID: 28938493
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Liraglutide downregulates hepatic LDL receptor and PCSK9 expression in HepG2 cells and db/db mice through a HNF-1a dependent mechanism.
    Yang SH; Xu RX; Cui CJ; Wang Y; Du Y; Chen ZG; Yao YH; Ma CY; Zhu CG; Guo YL; Wu NQ; Sun J; Chen BX; Li JJ
    Cardiovasc Diabetol; 2018 Apr; 17(1):48. PubMed ID: 29618348
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of PCSK9 inhibition in addition to standard lipid-lowering therapy in patients at high risk for vascular disease.
    Stam-Slob MC; van der Graaf Y; de Boer A; Greving JP; Visseren FLJ
    Int J Cardiol; 2018 Feb; 253():148-154. PubMed ID: 29306457
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardiovascular Outcomes of PCSK9 Inhibitors: With Special Emphasis on Its Effect beyond LDL-Cholesterol Lowering.
    Bandyopadhyay D; Ashish K; Hajra A; Qureshi A; Ghosh RK
    J Lipids; 2018; 2018():3179201. PubMed ID: 29770231
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities.
    Mbikay M; Sirois F; Mayne J; Wang GS; Chen A; Dewpura T; Prat A; Seidah NG; Chretien M; Scott FW
    FEBS Lett; 2010 Feb; 584(4):701-6. PubMed ID: 20026049
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.